It is a gathering of the top most renowned doctors in the field of IBD. It is an opportunity not to be missed to meet and discuss key topics with a highly select group of 150-200 colleagues.
3rd IBDH Annual Meeting in Seattle. Meeting offers you:
Relevant and engaging presentations by renowned speakers
A forum to collaborate with others and ask questions and share your experiences
A place to reflect upon and refine your own practices
Start: March 03 2018, 8:00 am
End: March 03 2018, 3:30 pm
Cost: You are our guests
Credits: 6 credits
Seattle Marriott Waterfront
2100 Alaskan Way, Seattle, WA 98121 – (800) 228-9290
We recommend going online for best rates or call Brian Hatzkilson at 949-851-5151
Microbiome in IBD
Dr. William DePaolo
Top Down versus Step Up Therapy for IBD
Dr. Ghassan Wahbeh
Biosimilars - The use in IBD
Dr. Anita Afzali
Choosing an IBD Treatment Beyond Conventional Therapy
Dr. Brian Feagan
Post-Operative Treatment in IBD
Dr. Bincy Abraham
Role of Chromoendoscopy for Dysplasia Surveillance
Dr. Thomas Ullman
Inflammatory Bowel & Rheumatologic Disease
Dr. George Munoz
Potential New Pathways and Agents in the Management of IBD
Dr. Scott D. Lee
Venue : Bell Harbor Conference Center
After completion of this activity, participants will be able to:
Review our current understanding of the microbiome and potential effects on IBD as well as the microbiome future research direction.
Describe current state of the availability and use of biosimilars in IBD.
Understand potential limitations and benefits of biosimilars for the treatment of IBD.
Assess if patients would be best treated with top down therapy vs step up therapy.
Describe currently available therapies beyond conventional therapy and understand the differences between the various therapy categories.
Recognize patient specific characteristics that would benefit from a particular class of medical therapy beyond conventional therapy
Describe what patient characteristics are considered high risk for post-operative recurrence of disease.
Understand which patients would benefit from post-operative medical therapy.
Describe which specific types of medical therapy should be used in the treatment of post-operative disease recurrence.
Recognize the relationship of IBD with rheumatologic conditions and rheumatologic symptoms that are associated with IBD.
Understand the risk of colon cancer in IBD and the role of chromoendoscopy in evaluation for dysplasia in IBD.
Describe newly available and emerging therapies for the management of IBD.
Understand how the new treatments fit into our current treatment paradigm, including any unique risks associated with new treatments.
This activity is jointly provided by Global Education Group and IBD Horizons
This activity is supported by an educational grant from Prometheus Laboratories Inc., Abbvie Inc. and Takeda Pharmaceuticals U.S.A., Inc
Adult and pediatric gastroenterologists, surgeons, radiologists, advanced registered nurse practitioners, physician assistants, registered nurses and pharmacists all involved in providing care for IBD patients.
Statement of Need/Program Overview
This activity is jointly provided by Global Education Group and IBD Horizons.
The management of IBD is highly dynamic with extensive, cutting-edge information deriving from a wealth of ongoing scientific, clinical, and therapeutic research programs. The mission of IBD Horizons® is to provide healthcare providers the opportunity to enhance their clinical knowledge by providing the most up-to-date information regarding the management of IBD. Cutting edge topics delivered by respected educators/leaders in the IBD field, as well as opportunities for interaction between the presenters and participants have been designed into the educational program.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and IBD Horizons. Global is accredited by the ACCME to provide continuing medical education for physicians.
* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 6 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
This educational activity for 6 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 6.0 contact hours (0.6 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-18-003-L01-P)
This is a knowledge based activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete and pass the post test as well as submit an evaluation/application for credit.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or
apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter – Reported Financial Relationship
Scott D. Lee
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
Ashley Marostica, RN, MSN – Nothing to disclose
Lindsay Borvansky – Nothing to disclose
Andrea Funk – Nothing to disclose
Liddy Knight – Nothing to disclose
Paul Strunc – Nothing to disclose
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and IBD Horizons do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.